Cytokinetics
- Market cap
- 8.50B
- P/E (TTM)i
- -8.47
- P/Bi
- -48.97
- EPSi
- -6.54
- Div yieldi
- 0.00%
- 52W posi
- 20%
Anonymous reader poll. Unscientific, not investment advice.
About Cytokinetics
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
- Founded
- 1997
- CEO
- Mr. Robert I. Blum
- Employees
- 673
- Headquarters
- South San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- cytokinetics.com
Company profile
- Exchange
- US
- Symbol
- CYTK
- Market-cap rank
- #1564
- Listing date
- 1970-01-01
- Market cap
- 8.50B
- Float cap
- 8.46B
- Shares out
- 139.02M
- Float shares
- 138.49M
Sectors & themes
Quote time 2026-10-08 07:00:10 · For reference only, not investment advice and not tailored to your situation.